IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
EMERGE TREMFYANTTM: IMPROVEMENT IN PHYSICAL FUNCTION1,3
Mean change from baseline in HAQ-DI at Week 24
‡P<0.0001 vs placebo.
HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing:
- Activities of daily living
HAQ-DI=Health Assessment Questionnaire-Disability Index.
*Multiple imputation was used to impute missing data.
†Through Week 24, patients were considered to have no improvement (change=0) after meeting treatment failure criteria: discontinued study agent for any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 4. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.